文献速递肿瘤 PET/CT甲状腺核医学

68Ga-NODAGA-Exendin-4 PET/CT 提高局灶性先天性高胰岛素血症检出

68Ga-NODAGA-Exendin-4 PET/CT Improves the Detection of Focal Congenital Hyperinsulinism.
PubMed 文献 · J Nucl Med · 2021-07-02

本研究在19例先天性高胰岛素血症(CHI)患者术前对比18F-DOPA PET/CT与68Ga-NODAGA-exendin-4 PET/CT对局灶性病变的检出性能。

要点

  • 68Ga-NODAGA-exendin-4 PET/CT临床判读敏感度100%,高于18F-DOPA的71%。
  • 68Ga-NODAGA-exendin-4观察者间一致性Fleiss κ=0.91,优于18F-DOPA的0.56。
  • 68Ga-NODAGA-exendin-4靶/非靶比值2.02±0.65,显著高于18F-DOPA的1.40±0.40(P=0.021)。

核心结论

  • 对局灶性CHI的检出,68Ga-NODAGA-exendin-4 PET/CT临床敏感度高于18F-DOPA PET/CT且观察者间一致性更好。
  • 更好的对比度和图像质量使68Ga-NODAGA-exendin-4 PET/CT在外科医生术中定位病变方面优于18F-DOPA PET/CT。

研究设计与样本

  • 19例CHI患者术前均接受18F-DOPA PET/CT和68Ga-NODAGA-exendin-4 PET/CT检查。
  • 图像采用标准临床判读、盲法专家判读和联合判读三种方式评估,并以SUVmax计算靶(病变)/非靶(正常胰腺)比值。
  • 图像质量由小儿外科医生通过问卷评分。

主要发现

  • 基于临床判读,68Ga-NODAGA-exendin-4 PET/CT敏感度为100%(95%CI 77%-100%),18F-DOPA PET/CT为71%(95%CI 42%-92%)。
  • 68Ga-NODAGA-exendin-4的观察者间一致性Fleiss κ=0.91,18F-DOPA为0.56。
  • 68Ga-NODAGA-exendin-4靶/非靶比值2.02±0.65,显著高于18F-DOPA的1.40±0.40(P=0.021)。
  • 小儿外科医生在5分制量表上评价68Ga-NODAGA-exendin-4 PET/CT图像质量优于18F-DOPA PET/CT。

临床怎么用

  • 对拟行局灶性病变切除的CHI患者,术前可考虑68Ga-NODAGA-exendin-4 PET/CT以提高病灶检出和定位信心。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Surgery with curative intent can be offered to congenital hyperinsulinism (CHI) patients, provided that the lesion is focal. Radiolabeled exendin-4 specifically binds the glucagonlike peptide 1 receptor on pancreatic β-cells. In this study, we compared the performance of 18F-DOPA PET/CT, the current standard imaging method for CHI, and PET/CT with the new tracer 68Ga-NODAGA-exendin-4 in the preoperative detection of focal CHI. Methods: Nineteen CHI patients underwent both 18F-DOPA PET/CT and 68Ga-NODAGA-exendin-4 PET/CT before surgery. The images were evaluated in 3 settings: a standard clinical reading, a masked expert reading, and a joint reading. The target (lesion)-to-nontarget (normal pancreas) ratio was determined using SUVmax Image quality was rated by pediatric surgeons in a questionnaire. Results: Fourteen of 19 patients having focal lesions underwent surgery. On the basis of clinical readings, the sensitivity of 68Ga-NODAGA-exendin-4 PET/CT (100%; 95% CI, 77%-100%) was higher than that of 18F-DOPA PET/CT (71%; 95% CI, 42%-92%). Interobserver agreement between readings was higher for 68Ga-NODAGA-exendin-4 than for 18F-DOPA PET/CT (Fleiss κ = 0.91 vs. 0.56). 68Ga-NODAGA-exendin-4 PET/CT provided significantly (P = 0.021) higher target-to-nontarget ratios (2.02 ± 0.65) than did 18F-DOPA PET/CT (1.40 ± 0.40). On a 5-point scale, pediatric surgeons rated 68Ga-NODAGA-exendin-4 PET/CT as superior to 18F-DOPA PET/CT. Conclusion: For the detection of focal CHI, 68Ga-NODAGA-exendin-4 PET/CT has higher clinical sensitivity and better interobserver correlation than 18F-DOPA PET/CT. Better contrast and image quality make 68Ga-NODAGA-exendin-4 PET/CT superior to 18F-DOPA PET/CT in surgeons' intraoperative quest for lesion localization.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Boss M, Rottenburger C, Brenner W, et al. 68Ga-NODAGA-Exendin-4 PET/CT Improves the Detection of Focal Congenital Hyperinsulinism. J Nucl Med. 2021. PMID: 34215672. doi:10.2967/jnumed.121.262327

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。